Year: 2017

10-Q – Quarterly report [Sections 13 or 15(d)]

HedgePath Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, HedgePath Pharmaceuticals, 2017, OCT 31, 2017, View Source [SID1234521352]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10-Q – Quarterly report [Sections 13 or 15(d)]

Array BioPharma has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Array BioPharma, 2017, OCT 31, 2017, View Source [SID1234521348]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10-Q – Quarterly report [Sections 13 or 15(d)]

Intellia Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Intellia Therapeutics, 2017, OCT 31, 2017, View Source [SID1234521345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference

On October 31, 2017 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Credit Suisse 26th Annual Healthcare Conference in Scottsdale, Arizona (Press release, Neurocrine Biosciences, OCT 31, 2017, View Source;p=RssLanding&cat=news&id=2312932 [SID1234521370]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Neurocrine Biosciences’ Cancer Pipeline, book your free 1stOncology demo here.

The live presentation takes place on Wednesday, November 8 at 9:30am ET (6:30am PT). The presentation will be webcast and may be accessed on the Company’s website at View Source

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 26th Annual Healthcare Conference

On October 31, 2017 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, Nov. 7, 2017 at 9:45 a.m. MT (11:45 a.m. ET/4:45 p.m. GMT) from The Phoenician in Scottsdale, AZ (Press release, Alkermes, OCT 31, 2017, View Source;p=RssLanding&cat=news&id=2312944 [SID1234521365]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Alkermes’ Cancer Pipeline, book your free 1stOncology demo here.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.